High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma

Chen, Ming-Huang; Hsiao, Liang Tsai; Chiou, Tzeon Jye; Liu, Jin Hwang; Gau, Jyh Pyng; Teng, Hao Wei; Wang, Wei Shu; Chao, Ta‐Chung; Yen, Chueh Chuan; Chen, Po Min

doi:10.1007/s00277-008-0469-9

Cited by 96 publications

(110 citation statements)

References 31 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Testing of HBV surface antigen alone may in fact underestimate the true prevalence of chronic HBV infection in lymphoma patients. Indeed, a study from Taiwan 20 examining the sera of HBsAg-negative patients with B-cell non-Hodgkin lymphoma (NHL) and nonlymphoma solid tumors and healthy volunteers for the presence of HBV DNA found a statistically higher incidence of occult HBV infection in HBsAg-negative patients with B-cell NHL compared with others. Taken together, these data suggest a potential epidemiologic association between HBV and the development of malignant lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy

Koo

Tan

et al. 2009

Cancer

View full text Add to dashboard Cite

BACKGROUND: Individuals who had past hepatitis B virus (HBV) infection appeared to clear their serum hepatitis B surface antigen (HBsAg) while producing antibody to the hepatitis B core antigen (HBcAb), which is detectable in their serum. Currently, it is uncertain whether patients with past HBV infection require routine antiviral prophylaxis during chemotherapy, although some cancer agencies recommend its routine use. The objective of the current study was to determine the prevalence of past HBV infection in patients with lymphoma and its relevance in terms of HBVrelated complications. METHODS: The authors reviewed 430 patients with lymphoma from May 2006 to May 2008. RESULTS: Among the 430 patients, 233 had both the HBsAg and HBcAb tests performed, whereas 197 had only the HBsAg test performed. Among those with both tests performed, 34.3% (80 of 233) were HBcAb positive only. Of these 80 patients, 58 had a concomitant HBV DNA level test, which was positive in 3 (5.2%). Of the 67 patients with past and 26 with chronic HBV infection who received chemotherapy, HBV reactivation occurred in 1.5% and 42.3% of patients, respectively (P<.0001). Prophylactic lamivudine was administered in 7 (10.4%) patients with past HBV infection and in 18 (69.2%) with chronic HBV infection. CONCLUSIONS: The low rate of HBV reactivation reported in our study coupled with the high prevalence of past HBV infection in an endemic area suggests that routine usage of antiviral prophylaxis may not be required for all patients with past HBV infection. Close surveillance remains a reasonable and viable option for the majority of patients. Cancer 2010;116:115-21.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy

Koo

Tan

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

“…Recent reports examining HBV-DNA in serum have shown that occult HBV infection further adds to the associations of HBsAgpositive HBV infection with NHL and chronic lymphocytic leukemia. [30][31][32] It is also possible that some persons can be positive for HBV-DNA in hepatocytes or lymphocytes or both but negative in serum, which would further affect the association between HBV infection and NHL. …”

mentioning

confidence: 99%

Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities

Marcucci

Mele

2011

Blood

225

210

View full text Add to dashboard Cite

Over the past 2 decades considerable evidence has accumulated on the association between hepatitis C virus (HCV) and hepatitis B virus (HBV) and several hematologic malignancies, most notably B-cell non-Hodgkin lymphoma (NHL). In this review we summarize this evidence, address possible mechanisms whereby hepatitis viruses may contribute to lymphomagenesis, and discuss the therapeutic fallouts from this knowledge. Most of this evidence is on HCV, and this is the main focus of the review. Moreover, we mainly address the association with NHL, the most prevalent hematologic malignancy, and the most extensively investigated with regard to an association with hepatitis viruses. Available evidence on the association with other hematologic malignancies is also addressed briefly. (Blood. 2011;117(6):1792-1798) Hepatitis C virus and hepatitis B virusHepatitis C virus (HCV) is a positive, single-stranded RNA virus, member of the Flaviviridae family. 1 During its replicative cycle it goes through a negative-stranded RNA, but not DNA, intermediate, so that integration of HCV nucleic acid sequences into the host genome seems unlikely. As such, it lacks a pivotal property of classical oncogenic retroviruses. The HCV genome produces a single polyprotein that is proteolytically processed by viral and cellular proteases to produce structural (nucleocapsid, E1, E2) and nonstructural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B).Hepatitis B virus (HBV) is a small DNA virus, member of the Hepadnaviridae family. 2 It presents the unusual feature, for a DNA virus, to replicate through a RNA intermediate and can integrate into the host genome. Moreover, during replication, it undergoes transformation into covalently closed circular DNA. Detection of closed circular DNA HBV-, or negative-stranded HCV-intermediates is important because it identifies genuine viral replication instead of more trivial events such as viral absorption. HBV is characterized by a genome consisting of 4 overlapping open-reading frames: the S gene, encoding envelope proteins; the core gene, encoding the core and "e" proteins; the P gene, encoding DNA polymerase; and the X gene, encoding a transcriptional transactivator.Both viruses can induce acute and chronic hepatitis and are strongly associated with hepatocellular carcinoma (HCC). Epidemiology of non-Hodgkin lymphomaNon-Hodgkin lymphoma (NHL) is the hematologic malignancy with the highest prevalence worldwide. Incidence rates have grown fast up to the beginning of the new millennium, with an annual percentage increase of nearly 3%, which is faster than for most cancers. Thus, delay-adjusted Surveillance, Epidemiology and End Results incidence rate for all races was 11.06/100 000 in 1975, and 20.12/100 000 in 2002. Since then, incidence rates have started to level off, at least in some geographic areas, such as the United States (20.89 in 2007). 3 NHL incidence rates are higher in developed countries such as those in western Europe, North America, and Australia and lower in South America and Asia, but th...

show abstract

“…What is remarkable in our series is that 38.8% of HBV carriers were co-infected with HCV. Since HCV and HBV carriers are supposed to be more prone to the development of lymphoproliferative diseases [7], it should not be ruled out that a double viral infection determines an even greater risk of lymphoma occurrence [8].…”

Section: Letter To the Editormentioning

confidence: 99%

Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?

et al. 2008

View full text Add to dashboard Cite

show abstract

High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma

Cited by 96 publications

References 31 publications

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy

Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities

Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?

Contact Info

Product

Resources

About